Last update June 12, 2020

Abacavir (ABC)

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Abacavir is a nucleoside reverse transcriptase inhibitor with antiretroviral activity against HIV.
Indicated for children older than 3 mo.
Oral administration in one or two daily doses.

It is excreted in breast milk in clinically insignificant amounts (Shapiro 2013) and no problems have been observed in infants whose mothers have taken it (Kobbe 2016). Plasma levels in these infants were very low. (Shapiro 2013).

It can cause hyperprolactinemia and galactorrhea (Hutchinson 2000).

Mothers must be adviced that transmission of HIV infection by breastfeeding has been documented. However, mothers treated with Abacavir are at lower risk of HIV transmission through breastfeeding.
Según la política adoptada en cada país, la lactancia materna en madres con VIH / SIDA está o no aconsejada. Con el tratamiento antirretroviral de gran actividad (TARGA) la carga viral para VIH se puede reducir a cero, reduciendo el riesgo de transmisión de VIH a través de la lactancia materna a niveles semejantes a los de la alimentación con fórmula artificial.

See below the information of this related product:

  • Maternal Aids ( Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.)


We do not have alternatives for Abacavir (ABC) since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Abacavir (ABC) is also known as

Abacavir (ABC) in other languages or writings:


Abacavir (ABC) belongs to this group or family:


Main tradenames from several countries containing Abacavir (ABC) in its composition:


Variable Value Unit
Oral Bioavail. 83 %
Molecular weight 296 daltons
Protein Binding 49 %
VD 0,86 l/Kg
pKa 15,4 -
Tmax 2 hours
T1/2 1,5 hours
M/P ratio 0,85 -
Theoretical Dose 0,009 mg/Kg/d
Relative Dose 0,05 %
Ped.Relat.Dose 0,09 %


  1. WHO - World Health Organization Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Guideline. 2016 Abstract Full text (link to original source) Full text (in our servers)
  2. Kobbe R, Schalkwijk S, Dunay G, Eberhard JM, Schulze-Sturm U, Hollwitz B, Degen O, Teulen M, Colbers A, Burger D. Dolutegravir in breast milk and maternal and infant plasma during breastfeeding. AIDS. 2016 Nov 13;30(17):2731-2733. No abstract available. Abstract
  3. WHO. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach. Guideline. 2014 Full text (link to original source) Full text (in our servers)
  4. Shapiro RL, Rossi S, Ogwu A, Moss M, Leidner J, Moffat C, Lockman S, Moyo S, Makhema J, Essex M, Capparelli E. Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. Antivir Ther. 2013;18(4):585-90. Abstract
  5. Ribera E, Tuset M, Martín M, del Cacho E. Características de los fármacos antirretrovirales. [Characteristics of antiretroviral drugs]. Enferm Infecc Microbiol Clin. 2011 May;29(5):362-91. Abstract
  6. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, Makhema J, Moyo S, Thior I, McIntosh K, van Widenfelt E, Leidner J, Powis K, Asmelash A, Tumbare E, Zwerski S, Sharma U, Handelsman E, Mburu K, Jayeoba O, Moko E, Souda S, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010 Abstract Full text (link to original source)
  7. Hutchinson J, Murphy M, Harries R, Skinner CJ. Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors. Lancet. 2000 Sep 16;356(9234):1003-4. Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM